CARDIOME PHARMA CORP - COM NO PAR (CRME)

CUSIP: 14159U301

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class
Equity / COM NO PAR
Total 13F shares
18,166,978
Share change
-452,098
Total reported value
$38,734,105
Price per share
$2.13
Number of holders
26
Value change
-$1,016,296
Number of buys
10
Number of sells
13

Quarterly Holders Quick Answers

What is CUSIP 14159U301?
CUSIP 14159U301 identifies CRME - CARDIOME PHARMA CORP - COM NO PAR in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of CARDIOME PHARMA CORP - COM NO PAR (CRME) as of Q3 2017

As of 30 Sep 2017, CARDIOME PHARMA CORP - COM NO PAR (CRME) was held by 26 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 18,166,978 shares. The largest 10 holders included WESTFIELD CAPITAL MANAGEMENT CO LP, PUTNAM INVESTMENTS LLC, CLOUGH CAPITAL PARTNERS L P, Stonepine Capital Management, LLC, Tamarack Advisers, LP, Rock Springs Capital Management LP, AlphaOne Investment Services, LLC, RENAISSANCE TECHNOLOGIES LLC, JPMORGAN CHASE & CO, and Knott David M. This page lists 26 institutional shareholders reporting positions in this security for the Q3 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.